Potentiation of a Porous Silicon Therapeutic Vaccine in Colorectal Cancer via Oxaliplatin-Mediated Regulation of Myeloid-Driven Immunosuppression
Source abstract
Abstract
Although immunotherapy has shown great promise in treating various types of cancer, advanced tumors are often refractory due to a highly immunosuppressive tumor microenvironment (TME). We previously engineered a cancer therapeutic vaccine platform, µGCVax, by co-loading tumor antigen peptides, STING and TLR9 agonists into porous silicon microparticles. While effective in models with lower disease burden, its efficacy against advanced colorectal cancer (CRC) was less promising due to the accumulation of myeloid-derived suppressor cells (MDSCs) in TMEs. In this study, we investigated whether µGCVax-based immunotherapy in advanced CRCs could be potentiated via regulating MDSCs to reprogram the TME. In an advanced CT26 murine CRC model, we assessed µGCVax in combination with oxaliplatin, a standard CRC chemotherapeutic with established immunomodulatory effects. We demonstrated that oxaliplatin was preferentially taken up by monocytic MDSCs (M-MDSCs) and effectively reduced their abundance in the bone marrow, blood, spleen, and tumor. Relief of this immunosuppressive TME increased intratumoral infiltration of antigen-specific CD8+ T cells. Ultimately, the combination of oxaliplatin with µGCVax induced robust regression of established CRC tumors. These findings highlight that oxaliplatin synergizes with µGCVax by overcoming MDSC-mediated immunosuppression and enhancing antitumor immunity, representing a promising chemo-immunotherapy strategy for advanced CRC.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immune cells in cancer · Cancer Immunotherapy and Biomarkers · interferon and immune responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for BioNanoengineering, Houston Methodist Academic Institute, Houston, TX 77030, USA
Center for Immunotherapy and Neal Cancer Center, Houston Methodist Academic Institute, Houston, TX 77030, USA
Immunomonitoring Core, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA
School of Engineering Medicine/ENMED, Texas A&M University and Houston Methodist Hospital, Houston, TX 77030, USA
Funding
National Institute of Health · Golfers Against Cancer · PhRMA Foundation · Robert A. Welch Foundation
References (59)
Show source-provided references
1. Wu, S., Zhang, Y., Lin, Z., and Wei, M. (2025). Global burden of colorectal cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. BMC Cancer, 25.10.1186/s12885-025-15138-0 ↗
2. Cancer statistics, 2025
3. Current status of screening for colorectal cancer10.1093/annonc/mdt157 ↗
4. Colorectal cancer statistics, 2023
5. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study10.1200/JCO.19.02105 ↗
6. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study10.1016/S1470-2045(17)30422-9 ↗
7. Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)10.1158/1078-0432.CCR-20-1803 ↗
8. Advancements in immunotherapy for colorectal cancer treatment: A comprehensive review of strategies, challenges, and future prospective10.1007/s00384-024-04790-w ↗
9. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results10.1038/s41591-025-03876-4 ↗
10. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms10.3389/ebm.2024.10021 ↗
11. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: The phase 1 AMPLIFY-201 trial10.1038/s41591-023-02760-3 ↗
12. Checkpoints and beyond—Immunotherapy in colorectal cancer10.1016/j.semcancer.2018.04.003 ↗
13. Immunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance10.1016/j.critrevonc.2025.104775 ↗
14. A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC)10.1200/JCO.2025.43.4_suppl.LBA13 ↗
15. Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine10.1002/advs.202100166 ↗
16. A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine10.1016/j.trsl.2022.06.004 ↗
17. Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy10.1158/0008-5472.CAN-17-3415 ↗
18. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy10.1186/s12943-024-02208-3 ↗
19. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation10.1016/j.immuni.2016.01.014 ↗
20. Myeloid-derived suppressor cells: An emerging target for anticancer immunotherapy10.1186/s12943-022-01657-y ↗
21. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment10.1016/j.it.2016.01.004 ↗
22. Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review)10.3892/ijo.2024.5673 ↗
23. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment10.1038/s41423-019-0306-1 ↗
24. Cellular processing of platinum anticancer drugs10.1038/nrd1691 ↗
25. Novel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm10.1016/j.biomaterials.2024.122835 ↗
26. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—A randomized trial of the German AIO CRC study group10.1200/JCO.2010.31.1936 ↗
27. Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model10.1038/s41598-023-29363-9 ↗
28. Immunogenic death of colon cancer cells treated with oxaliplatin10.1038/onc.2009.356 ↗
29. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice10.1136/gut.2010.211722 ↗
30. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages10.1016/j.canlet.2019.10.020 ↗
31. Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-kappaB signaling10.1002/cam4.1878 ↗
32. Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients10.1080/2162402X.2021.1935557 ↗
33. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy10.1016/j.immuni.2015.11.024 ↗
34. Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine10.2147/IJN.S341394 ↗
35. The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells10.4049/jimmunol.2100719 ↗
36. PeacoQC: Peak-based selection of high quality cytometry data10.1002/cyto.a.24501 ↗
37. Myeloid-Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations10.1002/mco2.70231 ↗
38. Behind the monocyte’s mystique: Uncovering their developmental trajectories and fates10.1093/discim/kyad008 ↗
39. Regulation of immune responses by L-arginine metabolism10.1038/nri1668 ↗
40. CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer10.1158/0008-5472.CAN-16-3199 ↗
41. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression10.1038/s41416-018-0333-1 ↗
42. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study10.1016/S0140-6736(23)02268-7 ↗
43. The immune microenvironment of colorectal cancer10.1038/s41568-025-00872-1 ↗
44. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer10.1016/j.ejca.2020.06.030 ↗
45. Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice10.1136/jitc-2024-010791 ↗
46. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma10.1136/gutjnl-2018-317257 ↗
47. Myeloid-derived suppressor cells coming of age10.1038/s41590-017-0022-x ↗
48. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways10.1016/j.immuni.2014.10.020 ↗
49. LA-ICP-TOFMS Imaging Reveals Significant Influence of Cancer Cell Resistance on Oxaliplatin Compartmentalization in the Tumor Microenvironment10.1021/jacsau.5c00217 ↗
50. The impact of hypoxia on tumor-associated macrophages10.1172/JCI84427 ↗
51. Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages10.1172/jci.insight.178146 ↗
52. PI3Kgamma in Tumour Inflammation: Bridging Immune Response and Cancer Progression-A Mini-Review10.1111/imm.13959 ↗
53. Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils10.18632/oncotarget.2556 ↗
54. Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics10.1158/1078-0432.CCR-13-3141 ↗
55. Advancing translational research for colorectal immuno-oncology10.1038/s41416-023-02392-x ↗
56. The consensus molecular subtypes of colorectal cancer10.1038/nm.3967 ↗
57. Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer10.1158/1078-0432.CCR-21-0529 ↗
58. Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer10.18632/oncotarget.3682 ↗
59. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance10.1158/2326-6066.CIR-22-0116 ↗